FCA authorised · FRN 724952 0117 325 0027Quote & buy →
Mid-market insurance
Diagnostic kit and reagent manufacturer insurance is the set of liability, recall, property and management covers protecting businesses that make IVD tests and reagents. It matters because a wrong result can harm patients and customers long after sale.
Part of: Medical technology insurance
In short
IVD and reagent manufacturers usually need products liability, product recall, property and business interruption with deterioration of stock cover, employers' liability, cyber and management liability. The distinctive risk is a wrong result rather than a physical injury, so check how your wordings treat financial loss, efficacy and recall. IVDs must be registered with the MHRA before going on the GB market, and the Consumer Protection Act 1987 imposes strict liability on producers with a ten-year longstop. Review your programme when you add assays, territories, services or investors.
A UK manufacturer of in vitro diagnostic (IVD) kits, assays and reagents usually needs a programme built around products liability, product recall, property and business interruption (with cover for temperature-sensitive stock), employers' liability, cyber and management liability. If you also run a testing or interpretation service, professional indemnity (PI) sits alongside the products cover.
What makes IVD different from most medical device businesses is that your product rarely touches a patient. The harm comes from a wrong answer: a false negative that delays treatment, a false positive that triggers unnecessary treatment, or a batch that drifts out of specification. That shifts the questions towards financial loss, recall cost and how your wordings treat advice and results, rather than physical injury alone.
The table below maps the exposures we see most often in IVD and reagent manufacturing to the cover that usually responds. Every policy is subject to its own terms, limits and exclusions.
| Exposure | Cover that usually responds | Points to check |
|---|---|---|
| Patient harmed after a false negative or false positive result | Products liability | Whether pure financial loss to a laboratory or health service customer is covered or excluded |
| Batch failure leading to a field safety corrective action | Product recall or product guarantee | Recall is commonly excluded from products liability and bought separately |
| Freezer, cold room or power failure spoiling reagents | Property with deterioration of stock extension | Alarm and monitoring conditions, and the time limit before cover applies |
| Contamination or fire in a clean room or production suite | Property damage and business interruption | Indemnity period long enough to re-validate the line |
| Staff exposed to biological agents or hazardous chemicals | Employers' liability | Disease wording and records of COSHH controls |
| Error in a testing, validation or interpretation service | Professional indemnity | Whether the products policy has a design or advice extension, and the gap between the two |
| Ransomware hitting LIMS, batch records or ERP | Cyber | Business interruption from system outage, and incident response |
| Cold chain shipments damaged or delayed in transit | Goods in transit or marine cargo | Temperature deviation is often excluded unless specifically agreed |
| Claims against directors after a regulatory failure or funding dispute | Management liability or D&O | Investigation costs and regulator interviews |
In Great Britain, IVDs are regulated as medical devices under the Medical Devices Regulations 2002 (UK MDR 2002). The MHRA's guidance on regulating medical devices in the UK sets out the essentials:
On liability, Part I of the Consumer Protection Act 1987 makes producers, own-branders and importers into the UK strictly liable for damage caused by a defective product, subject to a ten-year longstop under section 11A of the Limitation Act 1980. That longstop is why products cover and run-off matter long after a kit is discontinued.
Illustrative. A reagent lot used in a widely sold immunoassay produces readings at the edge of specification. Complaints trend upward, the manufacturer opens a field safety corrective action and replaces stock at several hundred laboratories. The cost of notification, retrieval and replacement usually falls to a product recall policy, not products liability. If a patient later claims a delayed diagnosis, that claim is the products liability insurer's.
Illustrative. A compressor fails and the monitoring alarm goes unanswered. Several weeks of finished kits and enzyme stock spoil. Deterioration of stock cover usually responds if the alarm and maintenance conditions were met; the lost sales fall to business interruption, provided the policy links interruption to the insured damage.
Illustrative. The manufacturer's services arm validates a customer's analyser workflow and misses a cross-reactivity issue. The customer's loss is financial, not physical, so the claim usually sits with PI rather than products liability.
A clear submission usually helps underwriters understand an IVD risk and price it on its merits. Information that typically helps:
Growing IVD businesses often outgrow their insurance quietly. It is worth a structured insurance programme review when:
For the wider picture, see medical technology insurance and life sciences and biotech insurance. Apex arranges insurance for diagnostics and reagent manufacturers; a broker reads every enquiry.
It can, if the false negative leads to bodily injury, such as a delayed diagnosis, and the claim falls within the policy terms. Claims for purely financial loss, such as a laboratory's cost of retesting, are often excluded or limited unless the wording has a financial loss or efficacy extension. Check how your policy treats both.
For many IVD makers it is, because recall costs are commonly excluded from products liability. A field safety corrective action can mean notifying customers, retrieving stock, replacing lots and investigating root cause. Recall cover can usually be tailored to these costs, subject to the policy terms and any waiting periods.
Yes. MHRA guidance says IVDs must be registered before they are placed on the Great Britain market, and IVDs used in performance evaluation must be registered by the time the study starts. Manufacturers outside the UK act through a UK Responsible Person. Northern Ireland follows EU rules.
Most commercial property policies need a specific deterioration of stock extension for this. Insurers usually set conditions around temperature monitoring, alarm response and maintenance of refrigeration plant, so make sure the conditions match how your site actually runs, including weekends and holidays.
The Employers' Liability (Compulsory Insurance) Regulations 1998 require cover of at least £5 million for any one occurrence. Most policies provide higher limits as standard. Laboratories handling biological agents should also expect questions on COSHH controls and health surveillance.
Send us your current schedules or renewal pack and we will review the whole programme and tell you plainly what to keep and what to change. No fee and no obligation. Or call 0117 325 0027.
Book a programme review Get a quoteApex Insurance Brokers Limited is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales, company number 07014570. This page is general information, not advice on your individual circumstances, and it does not guarantee that cover will be available or on what terms.
